MediWound Ltd. (NASDAQ:MDWD) shareholders are probably feeling a little disappointed, since its shares fell 9.5% to US$12.90 in the week after its latest quarterly results. Statutory results overall were mixed, with revenues coming in 47% lower than the analysts predicted. What's really surprising is that losses of US$0.46 per share were 35% smaller than what was predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on MediWound after the latest results.
Taking into account the latest results, the current consensus from MediWound's five analysts is for revenues of US$29.2m in 2027. This would reflect a sizeable 191% increase on its revenue over the past 12 months. Per-share losses are expected to explode, reaching US$2.20 per share. Before this latest report, the consensus had been expecting revenues of US$31.8m and US$2.20 per share in losses.
Check out our latest analysis for MediWound
There was no real change to the average price target of US$29.67, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on MediWound's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic MediWound analyst has a price target of US$36.00 per share, while the most pessimistic values it at US$25.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the MediWound's past performance and to peers in the same industry. One thing stands out from these estimates, which is that MediWound is forecast to grow faster in the future than it has in the past, with revenues expected to display 135% annualised growth until the end of 2027. If achieved, this would be a much better result than the 11% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 8.6% annually. Not only are MediWound's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. They also downgraded MediWound's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple MediWound analysts - going out to 2028, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 1 warning sign for MediWound you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.